Barbara K. Finck, M.D., Appointed to ReForm Biologics Board of Directors

芭芭拉·K·芬克,医学博士,被任命改革生物制品公司董事会

2021-03-16 21:30:07 BioSpace

本文共1324个字,阅读需4分钟

Brings 25 years of preclinical and clinical drug development experience to ReForm WOBURN, Mass.--(BUSINESS WIRE)-- ReForm Biologics, a company developing a new generation of bio-innovative biologic medicines to improve patient access, safety and convenience, today announced the appointment of Barbara Finck, M.D., to its Board of Directors. Dr. Finck is currently the acting Chief Medical Officer at Coherus BioSciences. “Dr. Finck’s experience in the successful clinical development of groundbreaking therapies such as Ditropan-XL® and Enbrel® will be invaluable to ReForm Biologics as we pivot to the in-house development of our own bio-innovative medicines,” said Jim Sherblom, Chairman of the Board. “Barbara’s unwavering commitment to the development of therapies that improve and extend human lives will help guide the development of biologics that can be more easily and safely administered to patients living with debilitating illnesses. We look forward to working with Barbara as we build our clinical capabilities at ReForm.” “Biologics have changed the way we treat disease but they generally require in-clinic intravenous infusions that are inconvenient and often difficult to administer to fragile patients, particularly children who have smaller veins,” said Dr. Finck. “ReForm’s ability to reformulate biologics provides the opportunity to deliver these proven therapies in the clinic or at home through subcutaneous injections that could be safe, more convenient and encourage better compliance. I look forward to working with the ReForm team to improve patient care by making biologics more accessible for patients.” Dr. Finck is a board certified rheumatologist with more than 25 years of preclinical and clinical drug development experience in academic and biopharmaceutical settings. Dr. Finck, whose drug development activities have spanned multiple therapeutic areas, started her pharmaceutical career at ALZA as medical director for early clinical development of Ditropan-XL®, to treat spasms of the bladder. She subsequently held senior level positions at a half-dozen innovative biopharmaceutical companies. At Immunex (later acquired by Amgen), she was lead medical director for the Phase III clinical development of Enbrel® in rheumatoid arthritis and juvenile idiopathic arthritis. At Eos Biotechology, she was VP of Clinical Development. In addition, she was on the executive teams at PDL Biopharma (VP, Clinical Development), Osprey Pharmaceuticals USA, Inc. (Senior VP, Research and Development, and Chief Medical Officer), and NKT Therapeutics, Inc. (Chief Medical Officer). In her role as the Chief Medical Officer at Coherus, she was instrumental in the development and approval of UDENYCA®, a biosimilar pegfilgrastim. About ReForm Biologics ReForm Biologics creates gentler therapies for fragile patients, including pediatric patients, by using our proprietary technology to transform intravenous drugs into subcutaneous injections, to reduce adverse reactions, and to improve drug stability. Our goal is to enhance comfort, convenience, safety and compliance so that patients living with debilitating diseases can experience a better life while treating their medical conditions. For more information, visit www.reformbiologics.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005044/en/ Rob Kloppenburg Shoreline Biotech Communications (617) 930-5595 Source: ReForm Biologics View this news release online at: http://www.businesswire.com/news/home/20210316005044/en
将25年临床前和临床药物开发经验带到改革 马萨诸塞州沃本--(商业电讯)--改革生物制品公司,一家开发新一代生物创新生物药物以改善病人获得、安全性和便利性的公司,今天宣布任命芭芭拉芬克医学博士为其董事会成员。芬克博士目前是Coherus Biosciences的代理首席医疗官。 “博士说。Finck公司在Ditropan-XL®公司和Enbrel®公司等开创性疗法的成功临床开发方面的经验,在我们转向内部开发我们自己的生物创新药物时,对于改革生物制品将是非常宝贵的。“董事会主席吉姆·舍布洛姆说。“芭芭拉公司坚定不移地致力于开发改善和延长人类寿命的疗法,这将有助于指导生物制剂的开发,使其更容易和安全地应用于患有衰弱疾病的患者。我们期待着与芭芭拉合作,以建立我们的临床改革能力。“ 芬克博士说:“生物制剂改变了我们治疗疾病的方式,但它们通常需要在诊所内进行静脉输液,这对脆弱的病人,尤其是静脉较小的儿童来说,很不方便,而且常常很难给药。”“Reform公司重新配制生物制剂的能力为在诊所或家中通过皮下注射提供了机会,这可能是安全的,更方便的,并鼓励更好的依从性。我期待着与改革小组合作,通过让病人更容易获得生物制剂来改善病人护理。“ 芬克博士是一位董事会认证的风湿病学家,在学术和生物制药领域拥有超过25年的临床前和临床药物开发经验。Finck博士的药物开发活动涉及多个治疗领域,她在ALZA公司开始了她的制药生涯,担任治疗膀胱痉挛的Ditropan-XL®早期临床开发的医学主任。她随后在六家创新生物制药公司担任高级职位。在Immunex公司(后来被Amgen收购),她是Enbrel®治疗类风湿性关节炎和幼年特发性关节炎的III期临床开发的首席医疗总监。在Eos Biotechology,她是临床开发副总裁。此外,她还在PDL Biopharma(临床开发副总裁)、Osprey Pharmaceuticals USA,Inc.(研发高级副总裁兼首席医疗官)和NKT Therapeutics,Inc.(首席医疗官)担任执行团队成员。作为Coherus的首席医疗官,她帮助开发和批准了Udenyca®,这是一种生物类似的PEGFILGRASTIM。 关于改革生物制剂 ReForm Biologics通过使用我们的专有技术将静脉注射药物转变为皮下注射,以减少不良反应,并提高药物稳定性,为脆弱的患者,包括儿科患者创造更温和的疗法。我们的目标是增强舒适性、便利性、安全性和依从性,让生活在衰弱性疾病中的患者在治疗其医疗状况的同时体验更好的生活。欲了解更多信息,请访问www.reformbiologics.com。 在businesswire.com上查看源版本:https://www.businesswire.com/news/home/20210316005044/en/ 罗布·克洛彭堡 海岸线生物技术通讯 (617)930-5595 资料来源:ReForm Biologics 请在以下网址联机查看此新闻稿: http://www.businesswire.com/news/home/20210316005044/en

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文